Oric Pharmaceuticals, Inc. (ORIC) Financials
Annual revenue, profitability and per-share results for Oric Pharmaceuticals, Inc., as reported in SEC filings.
Revenue • FY2025
$0
Net income • FY2025
-$129.47M
▼ 1.3%YoY
Diluted EPS • FY2025
-$1.47
▲ 19.7%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $0 | -$129.47M | — | -$1.47 | -$111.68M | — | — |
| FY2024 | $0 | -$127.85M | — | -$1.83 | -$113.85M | — | — |
| FY2023 | $0 | -$100.7M | — | -$1.96 | -$86.54M | — | — |
| FY2022 | $0 | -$89.12M | — | -$2.25 | -$77.22M | — | — |
Figures as reported in Oric Pharmaceuticals, Inc.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a ORIC filing.
Get an email when ORIC files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.